Curtis Tyree is Senior Vice President, Strategy and Business Development, at Organovo. He is responsible for corporate partnerships, acquisitions, and R&D strategy. Prior to Organovo, Dr. Tyree held senior positions at HUYABIO, where he helped develop the immunomodulator HIYASTA^™ through approval in Japan. At TorreyPines Therapeutics he presented on the first gamma secretase modulators for Alzheimer’s Disease, and at Ligand Pharmaceuticals helped discover the thrombopoietin mimic Promacta^®. He holds a BSc in Microbiology & Immunology from McGill University and a PhD in Biology from UC San Diego. Dr. Tyree served as a founding member of the Advisory Board and as Adjunct Clinical Assistant Professor of Pharmacy Practice at the KGI School of Pharmacy and Health Sciences. He has served as an instructor and faculty member at the UC San Diego Division of Extended Studies.